Press releases

November 16, 2023

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

November 1, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium

October 4, 2023

ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer

September 12, 2023

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease

Reveal more

News and events

November 13, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics Host 2nd Annual Dark Genome Symposium

October 12, 2023

ROME honored in BostInno 2023 Fire Awards  |  BostInno

Reveal more

Scientific presentations

November 15, 2023

Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses  |  ACR Convergence 2023

November 9, 2023

Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription  |  EMBO Workshop: The Mobile Genome

Reveal more